MedTrace Logo

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2013-01-21

No results posted yet for this study

Summary

This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.

Conditions

  • Allergy

Interventions

DRUG

Xolair (omalizumab)

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Yamo Deniz, M.D. · Genentech, Inc.

Study Design

Purpose
TREATMENT

Eligibility

Min Age
6 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Completion
2006-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00086606 on ClinicalTrials.gov